Comments
Drug firm Caplin Point Laboratories on Monday said its subsidiary has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable portfolio.
As a part of the deal, Caplin Steriles, a wholly owned subsidiary of Caplin Point Laboratories Ltd, will out-license five of its injectable Abbreviated New Drug Applications (ANDAs) to Baxter Healthcare Corporation.
“Caplin Steriles Ltd has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs,” Caplin Point Laboratories said in a regulatory filing.
Specific terms of the agreement and financial details, however, were not disclosed.
“All these ANDAs have been developed in-house, and we are keen to license them to Baxter, who have an excellent sales and marketing infrastructure in the United States (US) for commercialisation of these products,” Caplin Point Laboratories Chairman C C Paarthipan said.
Shares of Caplin Point Laboratories were trading 2.36 per cent higher at Rs 396.45 apiece on the Bombay Stock Exchange (BSE).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.